All In Biotech

Drug Trial Radar · NCT06164951

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Nov 10, 2023

Primary completion

Dec 18, 2025

Study completion Dec 18, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QBGJ398-001).

Conditions

  • Achondroplasia

Interventions

  • Infigratinib 0.25 mg/kg/dayDrug

    Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg

  • Placebo Comparator 0.25 mg/kg/dayDrug

    Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline (BL) in annualized height velocity (cm/year)Time frame: Week 52

Locations

27 sites in 10 countries. Site status is shown where the registry gives one.

  • QED Investigative Site

    San Francisco, California

  • QED Investigative Site

    Aurora, Colorado

  • QED Investigative Site

    Baltimore, Maryland

  • QED Investigative Site

    Columbia, Missouri

  • QED Investigative Site

    Cincinnati, Ohio

  • QED Investigative Site

    Nashville, Tennessee

  • QED Investigative Site

    Madison, Wisconsin

  • QED Investigative Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • QED Investigative Site

    Parkville, Victoria, Australia

  • QED Investigative Site

    Edmonton, Alberta, Canada

  • QED Investigative Site

    London, Ontario, Canada

  • QED Investigative Site

    Ottawa, Ontario, Canada

  • QED Investigative Site

    Montreal, Quebec, Canada

  • QED Investigative Site

    Bron, France

  • QED Investigative Site

    Paris, France

  • QED Investigative Site

    Toulouse, France

  • QED Investigative Site

    Rome, Italy

  • QED Investigative Site

    Bergen, Norway

  • QED Investigative Site

    Oslo, Norway

  • QED Investigative Site

    Singapore, Singapore

  • QED Investigative Site

    Málaga, Spain

  • QED Investigative Site

    Vitoria-Gasteiz, Spain

  • QED Investigative Site

    Bristol, United Kingdom

  • QED Investigative Site

    Glasgow, United Kingdom

  • QED Investigative Site

    London, United Kingdom

  • QED Investigative Site

    Manchester, United Kingdom

  • QED Investigative Site

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.